Discover and read the best of Twitter Threads about #adaura
Most recents (6)
Folks! We return for #HOTrainees with the exciting #Day2 @myESMO #ESMO20 and some more #practice relevant studies in #breastcancer #ProstateCancer #lungcancer #GI, so sit back, relax and lets go through some data (#HO #trainee-style!) Shout out to @peters_solange @OncoAlert
1. #BreastCancer: We have #monarchE and #IMPassion031 hoping to hear from experts @ErikaHamilton9 @NicoleKuderer @DrSGraff @matteolambe @tmprowell @GeorgeSledge51 @VukovicPetra for more insights- please link to your discussions here for #trainees:
1. A) #monarchE: use of #abemiciclib in HR+, HER2-,high risk #EBC in addition to endocrine therapy.
Current #SOC: adjuvant ET (5-10 years)
#monarchE: #Abemaciclib + ET iDFS HR 0.747, here's a great summary by @ErikaHamilton9 for @OncoAlert :
Current #SOC: adjuvant ET (5-10 years)
#monarchE: #Abemaciclib + ET iDFS HR 0.747, here's a great summary by @ErikaHamilton9 for @OncoAlert :
@myESMO #ESMO20 as a #trainee can be #overwhelming! So many good studies, some more #practicechanging then others, if you missed some and want to understand (albeit at a simplistic #trainee level), sit back, relax and enjoy as we go through some great data #ESMO20 @OncoAlert
1. #NSCLC: 2 major studies #ADAURA #CROWN for adjuvant #EGFRmNSCLC, and advanced #ALK+ experts can provide better perspective @JackWestMD @n8pennell @StephenVLiu @AMansfieldMD @CharuAggarwalMD @NarjustDumaMD @GlopesMd @DevikaDasMD @OncoAlert
1. A) #ADAURA: Stage IB-IIIA #resected #NSCLC with #EGFRm treated with #Osimertinib vs #placebo [SOC prior to this was adjuvant chemotherapy [cisplatin-based doublet based on #LACE metanalysis- pubmed.ncbi.nlm.nih.gov/18506026/] showed improvement in #DFS @NEJM nejm.org/doi/full/10.10…
#ESMO20 Key update on #ADAURA regarding CNS disease recurrence with adjuvant osimertinib vs placebo after resected stage IB-III #EGFR mutant NSCLC. #LCSM @OncoAlert @myESMO
#ESMO20 We saw at #ASCO20 the positive results from #ADAURA where adjuvant osimertinib significantly improved DFS in resected stage II/III NSCLC (DFS HR 0.17). Pre-specified analysis CNS recurrence given tropism of the disease and CNS efficacy of osimertinib. #LCSM
#ESMO20 Patients receiving osimertinib were less likely to recur overall but when there was recurrence, it was less likely to be distant. #LCSM @OncoAlert
Time to weigh in with a thread on the #ADAURA trial presented at #ASCO20. I have been thinking about it carefully and listening to the chatter on #Twitter and other sites. Have also watched w/ interest the back and forth b/t @jackWestMD and @n8pennell #lcsm
#ASCO20 Discussion of #ADAURA provided by @dave6408 of @SarahCannonDocs reminding us why we give adjuvant therapy after surgery for NSCLC. Are we curing or are we controlling/delaying? We view toxicity (physical and financial) differently in these two situations. #OncoAlert
#ASCO20 In the #EGFR setting, we have several trials that laid the groundwork for what we saw in #ADAURA: RADIANT (adjuvant erlotinib vs placebo but included EGFRmt and wt), SELECT (EGFR+ but single arm), and ADJUVANT (gef vs chemo). #OncoAlert #LCSM
#ASCO20 The DFS HR is impressive but some questions about surgery imbalances, chemo delivery (a lot of pts did not get chemo). Overall, @dave6408 was not on the fence though and declared #EGFR testing and adjuvant osimertinib our new standard. #OncoAlert #LCSM
#ASCO20 Highly anticipated plenary presentation of #ADAURA by @DrRoyHerbstYale: 3y of adjuvant osimertinib after resection of #EGFR+ NSCLC #OncoAlert #LCSM
#ASCO20 In the advanced setting, #EGFR TKI therapy is our clear standard. Relatively rapid implementation and the current SOC for stage IV NSCLC is osimertinib. #LCSM #OncoAlert
